Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study

We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with a...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2022-01, Vol.63 (2), p.416-425
Main Authors: Gjærde, Lars Klingen, Rank, Cecilie Utke, Andersen, Mette Klarskov, Jakobsen, Lasse Hjort, Sengeløv, Henrik, Olesen, Gitte, Kornblit, Brian, Marquart, Hanne, Friis, Lone Smidstrup, Petersen, Søren Lykke, Andersen, Niels Smedegaard, Nielsen, Ove Juul, Toft, Nina, Schjødt, Ida
Format: Article
Language:English
Subjects:
acute lymphoblastic leukemia
Adolescent
Adult
Aged
ALL
allogeneic hematopoietic stem cell transplantation
Allogeneic transplantation
Cohort Studies
Denmark - epidemiology
Hematopoietic Stem Cell Transplantation - adverse effects
Humans
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Retrospective Studies
survival
Transplantation Conditioning
Transplantation, Homologous
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000-2019. Patients had a median (min-max) age of 36 (18-74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27-66%) in year 2000 versus 77% (CI 59-88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00-1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93-1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87-0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93-1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2021.1992620